Evidence map›Paper›PMID 27771732›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2016

Class III β-Tubulin in Colorectal Cancer: Tissue Distribution and Clinical Analysis of Chinese Patients.

Xiaoli Zhao, Changli Yue, Jiamin Chen, Cheng Tian, Dongmei Yang, Li Xing, Honggang Liu, Yulan Jin

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. βIII-Tubulin Gene Regulation in Health and Disease.Frontiers in cell and developmental biology · 2022
    Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Xiaoli ZhaoDepartment of Pathology, Beijing Tongren Hospital, Capital Medical University and Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing, China (mainland).
Changli YueDepartment of Pathology, Beijing Tongren Hospital, Capital Medical University and Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing, China (mainland).
Jiamin ChenDepartment of Pathology, Beijing Tongren Hospital, Capital Medical University and Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing, China (mainland).
Cheng TianDepartment of Pathology, Beijing Tongren Hospital, Capital Medical University andBeijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing, China (mainland).
Dongmei YangDepartment of Pathology, Beijing Tongren Hospital, Capital Medical University and Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing, China (mainland).
Li XingDepartment of Pathology, Beijing Tongren Hospital, Capital Medical University and Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing, China (mainland).
Honggang LiuDepartment of Pathology, Beijing Tongren Hospital, Capital Medical University and Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing, China (mainland).
Yulan JinDepartment of Pathology, Beijing Tongren Hospital, Capital Medical University and Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing, China (mainland).
Beijing Tongren Hospital · CNCapital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Class III β-tubulin (βIII-tubulin) has been reported to express at the invasive margin of colorectal cancer. The present study aimed to investigate the clinical implication of βIII-tubulin expression at the invasive margin of colorectal cancer. MATERIAL AND METHODS We recruited 111 patients with surgically resected colorectal carcinoma for bIII-tubulin expression analysis. The cases with bIII-tubulin-positive tumor cells found only in the invasive front tumor area were assigned to the invasive front group, while the remaining cases were all assigned to the non-invasive front group. Clinical analysis of βIII-tubulin and other clinical data was performed. RESULTS The positive staining rates and staining intensity of bIII-tubulin were significantly different between the invasive and non-invasive front groups (p=0.001 and p=0.006), and there was a significant difference in tumor differentiation between the 2 groups (p=0.032). In the non-invasive front group, staining intensity of bIII-tubulin was significantly associated with positive staining rates and lymphatic metastasis (p<0.001 and p=0.048). CONCLUSIONS Our data showed the tissue distribution of bIII-tubulin expression at invasive margin or diffuse distribution. Expression of bIII-tubulin was correlated with tumor differentiation and lymphatic metastasis, suggesting a potential role of bIII-tubulin in tumor differentiation and metastasis. This study may shed light on bIII-tubulin as a novel potential molecular target for a new anti-cancer drug.

Indexed as

AgedAged, 80 and overAsian PeopleBiomarkers, TumorCell DifferentiationCell Line, TumorChinaColorectal NeoplasmsFemaleHumansLymphatic MetastasisMaleMiddle AgedRetrospective StudiesTubulinBiomarkers, TumorTubulin

Identifiers

PMID27771732
PMCPMC5088737
OpenAlexW2534777369

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.